Associations of cardiovascular agents and metformin with depression symptoms: A cross-sectional analysis from the HUNT Study, Norway

publishedVersio

Risk of antidepressant initiation among users of cardiovascular agents and metformin. Findings from the Trøndelag Health Study (HUNT) and Norwegian Prescription Database (NorPD), Norway

publishedVersio

Dual-emission luminescence thermometry using LaGaO3:TM3+, Ln3+ phosphors

The first biological window (650–950 nm) is the area within the NIR spectrum able to penetrate skin more effectively than shorter wavelengths.1 The TM3+, Ln3+ activator combination has attracted attention due excitation/emission within this wavelength range.2 In this investigation, a series of La1-xGa0.99O3: Cr0.01, Ndx phosphors (where x = 0.005, 0.01, 0.02) were synthesised by conventional solid-state methods and structurally characterised by Rietveld refinement of a structural model and powder diffraction data.3 Room temperature photoluminescence was undertaken with excitation spectra of both the Cr3+ and the Nd3+ showing energy transfer to the other emission centre alongside showing the characteristic Cr3+ broadbands, and sharp Nd3+ line excitations. Emission spectra showed both the Cr3+ 2E sharp peak at 729 nm, and the Nd3+ 4I3/2 4I9/2 emission of Nd3+ ca. 890 nm. Variable temperature thermometric analysis was undertaken, with the La1-xGa0.99O3: Cr0.01, Ndx (x = 0.02) sample exhibiting the emissions from the Cr3+ and Nd3+ centres at comparable intensities. Monitoring by luminescence intensity ratio (LIR) showed Cr3+ emission being quenched slower than Nd3+ emission. The phosphor produced a relative sensitivity of ~2.0% K-1 at 300 K, high absolute sensitivity, and a temperature resolution of 0.04 K at 300 K.ICOM&IWPPP 2022 : August 29 - September 2, 2022, Belgrad

The C-terminal extension unique to the long isoform of the shelterin component TIN2 enhances its interaction with TRF2 in a phosphorylation- and dyskeratosis congenita-cluster-dependent fashion

TIN2 is central to the shelterin complex, linking the telomeric proteins TRF1 and TRF2 with TPP1/POT1. Mutations in TINF2, which encodes TIN2, that are found in dyskeratosis congenita (DC) result in very short telomeres and cluster in a region shared by the two TIN2 isoforms, TIN2S (short) and TIN2L (long). Here we show that TIN2L, but not TIN2S, is phosphorylated. TRF2 interacts more with TIN2L than TIN2S, and both the DC-cluster and phosphorylation promote this enhanced interaction. The binding of TIN2L, but not TIN2S, is affected by TRF2-F120, which is also required for TRF2's interaction with end processing factors such as Apollo. Conversely, TRF1 interacts more with TIN2S than with TIN2L. A DC-associated mutation further reduces TIN2L-TRF1, but not TIN2S-TRF1, interaction. Cells overexpressing TIN2L or phosphomimetic-TIN2L are permissive to telomere elongation, whereas cells overexpressing TIN2S or phosphodead-TIN2L are not. Telomere lengths are unchanged in cell lines in which TIN2L expression has been eliminated by CRISPR/Cas9-mediated mutation. These results indicate that TIN2 isoforms are biochemically and functionally distinguishable, and that shelterin composition could be fundamentally altered in patients with TINF2 mutations

Cosmological expansion and local systems: a Lema\^{i}tre-Tolman-Bondi model

We propose a Lema\^{i}tre-Tolman-Bondi system mimicking a two-body system to address the problem of the cosmological expansion versus local dynamics. This system is strongly bound but participates in the cosmic expansion and is exactly comoving with the cosmic substratum

Spectral Stacking of Radio-Interferometric Data

Mapping molecular line emission beyond the bright low-J CO transitions is still challenging in extragalactic studies, even with the latest generation of (sub-)mm interferometers, such as ALMA and NOEMA. We summarise and test a spectral stacking method that has been used in the literature to recover low-intensity molecular line emission, such as HCN(1-0), HCO+(1-0), and even fainter lines in external galaxies. The goal is to study the capabilities and limitations of the stacking technique when applied to imaged interferometric observations. The core idea of spectral stacking is to align spectra of the low S/N spectral lines to a known velocity field calculated from a higher S/N line expected to share the kinematics of the fainter line, e.g., CO(1-0) or 21-cm emission. Then these aligned spectra can be coherently averaged to produce potentially high S/N spectral stacks. Here, we use imaged simulated interferometric and total power observations at different signal-to-noise levels, based on real CO observations. For the combined interferometric and total power data, we find that the spectral stacking technique is capable of recovering the integrated intensities even at low S/N levels across most of the region where the high S/N prior is detected. However, when stacking interferometer-only data for low S/N emission, the stacks can miss up to 50% of the emission from the fainter line. A key result of this analysis is that the spectral stacking method is able to recover the true mean line intensities in low S/N cubes and to accurately measure the statistical significance of the recovered lines. To facilitate the application of this technique we provide a public Python package, called PyStacker.Comment: 10 pages, 10 figures, accepted for pub in A&A, Apr 28, 202

Measuring Patient Compliance With Remote Monitoring Following Discharge From Hospital After Major Surgery (DREAMPath): Protocol for a Prospective Observational Study

BACKGROUND: The incidence of major surgery is on the rise globally, and more than 20% of patients are readmitted to hospital following discharge from hospital. During their hospital stay, patients are monitored for early detection of clinical deterioration, which includes regularly measuring physiological parameters such as blood pressure, heart rate, respiratory rate, temperature, and pulse oximetry. This monitoring ceases upon hospital discharge, as patients are deemed clinically stable. Monitoring after discharge is relevant to detect adverse events occurring in the home setting and can be made possible through the development of digital technologies and mobile networks. Smartwatches and other technological devices allow patients to self-measure physiological parameters in the home setting, and Bluetooth connectivity can facilitate the automatic collection and transfer of this data to a secure server with minimal input from the patient. OBJECTIVE: This paper presents the protocol for the DREAMPath (Domiciliary Recovery After Medicalization Pathway) study, which aims to measure compliance with a multidevice remote monitoring kit after discharge from hospital following major surgery. METHODS: DREAMPath is a single-center, prospective, observational, cohort study, comprising 30 patients undergoing major intracavity surgery. The primary outcome is to assess patient compliance with wearable and interactive smart technology in the first 30 days following discharge from hospital after major surgery. Secondary outcomes will explore the relation between unplanned health care events and physiological data collected in the study, as well as to explore a similar relationship with daily patient-reported outcome measures (Quality of Recovery-15 score). Secondary outcomes will be analyzed using appropriate regression methods. Cardiopulmonary exercise testing data will also be collected to assess correlations with wearable device data. RESULTS: Recruitment was halted due to COVID-19 restrictions and will progress once research staff are back from redeployment. We expect that the study will be completed in the first quarter of 2022. CONCLUSIONS: Digital health solutions have been recently made possible due to technological advances, but urgency in rollout has been expedited due to COVID-19. The DREAMPath study will inform readers about the feasibility of remote monitoring for a patient group that is at an increased risk of acute deterioration. TRIAL REGISTRATION: ISRCTN Registry ISRCTN62293620; https://www.isrctn.com/ISRCTN62293620. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/30638